Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Mar 28;48(1):48.
doi: 10.1186/s13052-022-01249-y.

L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report

Affiliations
Case Reports

L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report

Valentina Rovelli et al. Ital J Pediatr. .

Abstract

Background: Pompe disease (PD) is a disorder of glycogen metabolism conditioning a progressive and life conditioning myopathy. Enzyme replacement therapy (ERT) is currently the best treatment option for PD, but is not resolutive. While other potential therapeutic approaches have been reported before, these have never been tried as co- treatments. L-alanine oral supplementation (LAOS) has been proven to reduce muscle breakdown: we hereby report the first case of supplementation on a PD patient on ERT.

Case presentation: F. is a 9 y.o. infantile onset Pompe Disease (IOPD) girl ERT-treated since age 1 developing a progressive myopathy. We started her on LAOS and performed assessments at baseline, 6 and 9 months. At baseline, F.'s weight, height and BMI were within normal ranges, while body composition showed low fat mass -FM and high resting energy expenditure-REE levels. After LAOS, a progressive FM increase and REE reduction could be observed both at 6 and 9 months.

Conclusions: ERT is not curative for PD patients thus additional treatments could be considered to improve outcomes. Our patient showed physical signs of inability to accumulate energy when exclusively on ERT, while FM increase and REE reduction occurred when supplemented with LAOS, likely reflecting anabolic pathways' implementation. This is the first case reporting potential LAOS benefits in PD-on ERT patients. Longitudinal case control studies are yet needed to evaluate possible efficacy of combined LAOS And ERT treatment in PD patients.

Keywords: Body composition; Enzyme replacement therapy; L-alanine; Myopathy; Pompe Disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Time-REE correlations with LAOS, patient on treatment vs. expected patient’s REE without intervention. Shapiro–Wilk normality test and repeated-Measures ANOVA were performed (with statistical significance p-value set at < 0.05) for studying the variables at each studied time with data grouped into two categories. First group contained the variables of basal metabolism repeated at 3 times of our patient (red line). Second group contained instead the expected basal metabolism variables without intervention, obtained with three different formulas* (Harris Benedict-REE; Schofield-REE; WHO-REE) at same three different times and based on patient’s parameters (black line). A statistically significant association can be found between intervention and time with the basal metabolism of our patient (p-value 0.004)

Similar articles

Cited by

References

    1. A.J.J. Reuser, R. Hirschhorn, M.A. Kroos, Pompe Disease: Glycogen Storage Disease Type II, Acid α-Glucosidase (Acid Maltase) Deficiency, in: D.L. Valle, S. Antonarakis, A. Ballabio, A.L. Beaudet, G.A. Mitchell, The Online Metabolic and Molecular Bases of Inherited Disease. The McGraw-Hill Companies (2001), 3389–3420 https://ommbid.mhmedical.com/content.aspx?bookid=2709&sectionid=225890450).
    1. Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med. 2019;7:278. doi: 10.21037/atm.2019.04.13. - DOI - PMC - PubMed
    1. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356:397–398. doi: 10.1016/s0140-6736(00)02533-2. - DOI - PubMed
    1. Amalfitano A, McVie-Wylie AJ, Hu H, et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci USA. 1999;96:8861–8866. doi: 10.1073/pnas.96.16.8861. - DOI - PMC - PubMed
    1. Schoser B, Hill V, Raben N. Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics. 2008;5:569–578. doi: 10.1016/j.nurt.2008.08.009. - DOI - PMC - PubMed

Publication types